PMV Pharmaceuticals, Inc. - Common Stock (PMVP)
1.4300
-0.0100 (-0.69%)
PMV Pharmaceuticals Inc is a biotechnology company focused on the discovery and development of novel therapies that target specific genetic mutations in cancer
The company utilizes its proprietary platform to identify and design small molecule drugs aimed at treating a range of cancers by addressing the underlying genetic drivers of the disease. With a strong emphasis on precision medicine, PMV Pharmaceuticals strives to improve patient outcomes through innovative treatments that can selectively target and inhibit tumor growth associated with particular genetic alterations.
Previous Close | 1.440 |
---|---|
Open | 1.440 |
Bid | 1.330 |
Ask | 1.380 |
Day's Range | 1.395 - 1.440 |
52 Week Range | 1.320 - 2.260 |
Volume | 127,892 |
Market Cap | 65.46M |
PE Ratio (TTM) | -1.430 |
EPS (TTM) | -1.0 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 142,402 |
News & Press Releases
“Game-Changing Biotech Companies Making Waves: INBS, PMVP, TPST, OMGA, MRSN”
In the rapidly evolving biotech sector, a few standout companies are pushing boundaries and setting new standards. From Intelligent Bio Solutions' innovative drug testing technology to PMV Pharmaceuticals' promising clinical trial advancements, these trailblazers are not just making headlines—they're shaping the future of healthcare while improving the workplace. Discover how these five companies are leading the charge in innovation, with significant developments that could impact industries and lives worldwide.
Via AB Newswire · August 16, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
PMVP stock results show that PMV Pharma beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024
![](https://mms.businesswire.com/media/20240529460179/en/794671/5/FMI_horizontal.jpg)
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.
By Foundation Medicine · Via Business Wire · May 29, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
PMVP stock results show that PMV Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 9, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 13, 2023
![](https://cdn.benzinga.com/files/images/story/2023/10/13/image21.jpeg?width=1200&height=800&fit=crop)
Gainers Sigma Additive Solutions, Inc. (NASDAQSASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc.
Via Benzinga · October 13, 2023
![](https://cdn.benzinga.com/files/images/story/2023/10/12/pmvp.png?width=1200&height=800&fit=crop)
PMV Pharmaceuticals Inc (NASDAQPMVP) announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple tumor types and was well tolerated with a
Via Benzinga · October 12, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 12, 2023
![](https://cdn.benzinga.com/files/images/story/2023/09/22/image20.jpeg?width=1200&height=800&fit=crop)
Gainers MicroAlgo Inc. (NASDAQMLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.
Via Benzinga · September 22, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 9, 2023
![](https://cdn.benzinga.com/files/images/story/2023/08/09/cutera_-_logo.jpg?width=1200&height=800&fit=crop)
Gainers Tango Therapeutics, Inc. (NASDAQTNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss.
Via Benzinga · August 9, 2023
![](https://cdn.benzinga.com/files/images/story/2023/08/09/akamai_technologies_-_logo.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via Benzinga · August 9, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_3464.jpeg?width=1200&height=800&fit=crop)
On Friday, 135 companies reached new 52-week lows.
Via Benzinga · February 24, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_526.jpeg?width=1200&height=800&fit=crop)
Companies That Fell Through 52-Week Lows Monday During Monday's morning trading, 14 companies set new 52-week lows.
Via Benzinga · January 9, 2023
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_23351.jpeg?width=1200&height=800&fit=crop)
Monday saw 196 companies set new 52-week lows.
Via Benzinga · December 12, 2022
![](https://cdn.benzinga.com/files/images/story/2022/11/17/image18.jpg?width=1200&height=800&fit=crop)
Piper Sandler boosted the price target on Target Corporation (NYSETGT) from $190 to $200. Target shares fell 13.1% to close at $155.47 on Wednesday.
Via Benzinga · November 17, 2022
![](https://cdn.benzinga.com/files/images/story/2022/07/18/aapharma_9.png?width=1200&height=800&fit=crop)
Via Benzinga · July 18, 2022
![](https://cdn.benzinga.com/files/images/story/2022/06/08/yesterdays_movers.png?width=1200&height=800&fit=crop)
Gainers AeroClean Technologies, Inc. (NASDAQAERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.
Via Benzinga · June 8, 2022
![](https://investorplace.com/wp-content/uploads/2022/06/wall-street-red-light.jpg)
We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares.
Via InvestorPlace · June 7, 2022
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_9692.jpeg?width=1200&height=800&fit=crop)
During the Thursday's session, 100 stocks hit new 52-week lows.
Via Benzinga · June 2, 2022
![](https://cdn.benzinga.com/files/images/story/2022/06/01/yesterdays_movers.png?width=1200&height=800&fit=crop)
Gainers TherapeuticsMD, Inc. (NASDAQTXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners.
Via Benzinga · June 1, 2022